Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.
PLoS One. 2012;7(4):e34708. doi: 10.1371/journal.pone.0034708. Epub 2012 Apr 9.
To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 ARV-naïve, 78 ARV-exposed), pol amplicons were produced and analyzed for phenotypic resistance using both a subtype B- and C-backbone in which the pol fragment was deleted. Phenotypic resistance was assessed in resulting recombinant virus stocks (RVS) for a series of antiretroviral drugs (ARV's) and expressed as fold change (FC), yielding 1660 FC comparisons. These Antivirogram® derived FC values were categorized as having resistant or sensitive susceptibility based on biological cut-off values (BCOs). The concordance between resistance calls obtained for the same clinical sample but derived from two different backbones (i.e. B and C) accounted for 86.1% (1429/1660) of the FC comparisons. However, when taking the assay variability into account, 95.8% (1590/1660) of the phenotypic data could be considered as being concordant with respect to their resistance call. No difference in the capacity to detect resistance associated with M184V, K103N and V106M mutations was noted between the two backbones. The following was concluded: (i) A high level of concordance was shown between the two backbone phenotypic resistance profiles; (ii) Assay variability is largely responsible for discordant results (i.e. for FC values close to BCO); (iii) Confidence intervals should be given around the BCO's, when assessing resistance in HIV-1 subtype C; (iv) No systematic resistance under- or overcalling of subtype C amplicons in the B-backbone was observed; (v) Virus backbone subtype sequence variability outside the pol region does not contribute to phenotypic FC values. In conclusion the HXB2 virus backbone remains an acceptable vector for phenotyping HIV-1 subtype C pol amplicons.
迄今为止,大多数 HIV-1 表型耐药性检测都是使用 B 亚型病毒骨架(例如 HXB2)进行的。然而,使用这种骨架来确定非 B 亚型 HIV-1 病毒的耐药性仍然需要评估。从 114 份 HIV-1 亚型 C 临床样本(36 份未经抗逆转录病毒治疗,78 份经抗逆转录病毒治疗)中,产生了 pol 扩增子,并使用删除了 pol 片段的 B 型和 C 型骨架进行了表型耐药性分析。对一系列抗逆转录病毒药物(ARV)的重组病毒株(RVS)进行了表型耐药性评估,并表示为 fold change(FC),产生了 1660 个 FC 比较。根据生物学截断值(BCO),这些 Antivirogram® 衍生的 FC 值被归类为具有耐药性或敏感性。对于来自两种不同骨架(即 B 和 C)的相同临床样本获得的耐药性结果的一致性占 FC 比较的 86.1%(1429/1660)。然而,考虑到测定的变异性,95.8%(1590/1660)的表型数据可以被认为在其耐药性结果方面是一致的。在两种骨架之间,没有发现 M184V、K103N 和 V106M 突变相关耐药性检测能力的差异。得出以下结论:(i)两种骨架表型耐药性谱之间显示出高度一致性;(ii)测定的变异性是导致结果不一致的主要原因(即接近 BCO 的 FC 值);(iii)在评估 HIV-1 亚型 C 的耐药性时,应该在 BCO 周围给出置信区间;(iv)在 B 骨架中没有观察到对 C 亚型扩增子的系统耐药性低估或高估;(v)pol 区域以外的病毒骨架亚型序列变异性不会导致表型 FC 值。总之,HXB2 病毒骨架仍然是表型分析 HIV-1 亚型 C pol 扩增子的可接受载体。